MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement (WP4560)

Homo sapiens

Proposed signaling pathways by which MFAP5 induces LPP expression and increases the permeability and motility of endothelial cells via cytoskeleton rearrangement. The activation of the MFAP5-mediated signaling cascade in endothelial cells up-regulates LPP expression and subsequently promotes the motility of endothelial cells and the permeability of the endothelial cell monolayer. Adapted from supplemental figure 11 from [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785271/ Leung et al].

Authors

Kristina Hanspers , Friederike Ehrhart , Egon Willighagen , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

CPTAC ExRNA

Annotations

Disease Ontology

ovarian cancer

Cell Type Ontology

endothelial cell fibroblast neoplastic cell

Pathway Ontology

cancer pathway

Participants

Label Type Compact URI Comment
Ca2+ Metabolite chebi:29108
ITPR1 GeneProduct ensembl:ENSG00000150995
TJP1 GeneProduct ensembl:ENSG00000104067
ITGAV GeneProduct ensembl:ENSG00000138448
MYL2 GeneProduct ensembl:ENSG00000111245
PTK2 GeneProduct ensembl:ENSG00000169398
MAPK1 GeneProduct ensembl:ENSG00000100030
JUN GeneProduct ensembl:ENSG00000177606
MYLK GeneProduct ensembl:ENSG00000065534
MFAP5 GeneProduct ensembl:ENSG00000197614
VCL GeneProduct ensembl:ENSG00000035403
ITGB3 GeneProduct ensembl:ENSG00000259207
LPP GeneProduct ensembl:ENSG00000145012
ACTN1 GeneProduct ensembl:ENSG00000072110
CREB1 GeneProduct ensembl:ENSG00000118260
MAPK3 GeneProduct ensembl:ENSG00000102882
PXN GeneProduct ensembl:ENSG00000089159
PLCG1 GeneProduct ensembl:ENSG00000124181
PRKCQ GeneProduct ensembl:ENSG00000065675

References

  1. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, et al. J Clin Invest. 2018 Feb 1;128(2):589–606. PubMed Europe PMC Scholia